在科学探索中前进的肝癌肝移植  

Liver transplantation for hepatocellular carcinoma, advancing in scientific exploration

作　　者：陈昊[1] 李照[2] 朱继业[2] 徐骁 Chen Hao;Li Zhao;Zhu Jiye;Xu Xiao(Zhejiang University School of Medicine,Hangzhou 310058,China;Department of Hepatobiliary Surgery,Peking University People's Hospital,Beijing 100044,China;Hangzhou Medical College,Hangzhou 310059,China;National Center for Healthcare Quality Management in Liver Transplant,Hangzhou 310003,China)

机构地区：[1]浙江大学医学院,杭州310058 [2]北京大学人民医院肝胆外科,北京100044 [3]杭州医学院,杭州310059 [4]国家肝脏移植质控中心,杭州310003

出　　处：《中华普通外科杂志》2024年第5期329-332,共4页Chinese Journal of General Surgery

基　　金：国家重点研发计划(2021YFA1100504)。

摘　　要：肝移植治疗肝细胞癌疗效受术后肿瘤复发转移率居高不下的制约。为克服这一难题,患者的精确选择至关重要。术前降期治疗的目标是让超移植标准者转变为适宜移植。移植术后肿瘤复发转移的治疗难度大,亟待更多突破。免疫治疗作为一种新兴的治疗手段,其安全应用和疗效提升需进一步探索。免疫抑制策略也是减少肿瘤复发的关键因素,需精准评估和均衡掌控。The result of liver transplantation(LT)for the treatment of hepatocellular carcinoma(HcC)is constrained by the high rates of tumor recurrence and metastasis.To remove this bottleneck,precise patient selection is crucial for individuals with HCC,and the goal of down-staging therapy is to transform patients exceeding transplantation criteria into suitable candidates.The difficulty in treating tumor recurrence and metastasis post-transplantation calls for more breakthroughs.Immunotherapy,as an emerging treatment modality,requires further exploration to enhance its safety and efficacy.The immunosuppression strategy is also a key factor in reducing tumor recurrence,requiring precise assessment and balanced control.

关 键 词：癌 肝细胞 肝移植 复发 

分 类 号：R735.7[医药卫生—肿瘤]